FED UP with Bleeding Disorders Act of 2026
- Sponsor
- Rep. Johnson, Julie [D-TX-32]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- May 13, 2026
Bottom line
The FED UP with Bleeding Disorders Act of 2026 seeks to improve the diagnosis and treatment of bleeding disorders in women and girls through federal review, recommendations, and a national awareness campaign.
What it actually does
This bill directs the Secretary of Health and Human Services to conduct a comprehensive review of federal programs and research concerning bleeding disorders in women and girls, culminating in a public report with recommendations. Following this report, the bill authorizes competitive grants for a national public education and awareness campaign aimed at improving diagnosis and treatment for women and girls with bleeding disorders, particularly in rural and underserved areas.
Proponents argue
Supporters argue that the bill addresses a significant public health issue where women and girls with bleeding disorders are often undiagnosed for many years, leading to adverse health outcomes, unnecessary medical procedures like hysterectomies, and substantial economic costs. They emphasize the importance of specialized care, increased research, and targeted education to improve health equity and align with public health goals.
Opponents contend
Critics might argue that while the intent is laudable, the bill represents an expansion of federal programs and spending that could be addressed through existing public health initiatives or private sector efforts. Some might question the effectiveness of a federal awareness campaign compared to direct funding for treatment or research, or express concerns about the specific focus potentially diverting resources from other health priorities.
The bill is short and clearly written, making it highly accessible for any reader to understand its provisions and implications within a few minutes.
Section 3
Interagency Review Related to Bleeding Disorders in Certain Populations
This section requires the Secretary of Health and Human Services to lead a comprehensive review of federal programs, activities, and strategic plans concerning bleeding disorders in women and girls. The review must cover the state of science, provider training, access to treatment (including in rural and underserved areas), and inclusion in clinical research. A comprehensive report with recommendations for improvement and interagency coordination is due to Congress within two years, with a public comment period.
Supporters argue
Supporters argue this review is crucial for understanding the current landscape of care and research, identifying systemic gaps, and developing evidence-based strategies to address the long-standing diagnostic and treatment delays faced by women and girls with bleeding disorders.
Critics contend
No specific opposition is typically raised against a federal review and report, as it is a standard legislative mechanism for gathering information. However, some might argue it could be a bureaucratic exercise without guaranteed actionable outcomes.
Tradeoffs
The primary tension is between the need for comprehensive data and the potential for the review process to be lengthy or resource-intensive without immediate, tangible benefits for patients.
Section 4
National Public Education and Awareness Campaign
This section directs the Secretary of Health and Human Services to award competitive grants or contracts to public or private entities to conduct a national, evidence-based education and awareness campaign. The campaign, to be launched within one year of the report's publication, aims to improve awareness, diagnosis, and treatment of bleeding disorders in women and girls, specifically targeting both the affected population and various healthcare providers. It must include strategies for rural and underserved areas, culturally and linguistically appropriate resources, and an evaluation mechanism.
Defines "bleeding disorder" to include inheritable disorders like hemophilia, von Willebrand disease, and rare factor deficiencies, which impair blood clotting and can cause extended bleeding spontaneously or in response to injury, surgery, trauma, menstruation, or childbirth.
Section 3(d)
Why it matters:This is standard legislative practice to define terms within the section where they are most relevant or at the end of a major section. It's not necessarily evasive, but it does mean the precise scope of the bill's target conditions is not immediately apparent from the short title or initial provisions.
Case for: Supporters would argue that a clear, specific definition ensures that the review and awareness campaign focus on the intended medical conditions, preventing mission creep and ensuring resources are directed effectively to the most relevant patient populations.
Case against: No specific case against defining terms, but if the definition were too narrow or broad, it could be criticized for excluding or including conditions inappropriately. This definition appears medically sound and inclusive of the primary conditions targeted.
Estimated impact: Ensures the federal review and awareness campaign are precisely targeted to the specified inheritable bleeding disorders, impacting research, education, and treatment protocols for these conditions.